---
title: "From Data to Cure: A Comprehensive Exploration of Multi-omics Data Analysis for Targeted Therapies"
slug: "data-cure-comprehensive-exploration-multi-omics"
arxiv: ""
venue: "Molecular Biotechnology"
year: 2025
tags: [multi-omics, machine-learning, targeted-therapy, network-pharmacology, biomarker-discovery, drug-discovery, review]
importance: 2
date_added: 2026-04-30
source_type: tex
s2_id: ""
keywords: [multi-omics, big-data, machine-learning, targeted-therapeutics, network-pharmacology, genomics, transcriptomics, proteomics, metabolomics, epigenomics]
domain: "Computational Biology"
code_url: ""
cited_by: []
---

## Problem

Drug discovery for complex diseases is shifting from a "one drug target, one disease" paradigm to mechanism-driven, multi-target therapies. The single-omics view — looking at genomics, transcriptomics, proteomics, or metabolomics in isolation — is inadequate for capturing the layered regulatory interactions that drive disease. Each omics layer alone misses cross-layer cues: transcript abundance does not faithfully predict protein activity, metabolite concentrations can reflect either upstream regulation or downstream consumption, and epigenetic state interacts with metabolism in ways invisible to either layer alone. The challenge is how to integrate heterogeneous, high-dimensional, high-throughput omics datasets into a coherent picture that supports biomarker discovery, disease subtyping, and targeted therapy design.

## Key idea

Treat multi-omics integration as a machine-learning and network-pharmacology problem rather than a per-layer statistics problem. The review argues that ML algorithms — supervised (logistic regression, SVM, decision trees, random forest, naive Bayes, KNN, ANN, deep neural networks including CNN/RNN) and unsupervised (PCA, k-means, autoencoders) — combined with network models (protein-protein interaction, gene regulatory, metabolic, signaling, co-expression, miRNA-gene, drug-gene networks; both static and dynamic) form a unified pipeline that can: (1) refine disease classification beyond healthy-vs-diseased into subtypes; (2) discover biomarkers and prognostic signatures across omics layers; and (3) identify multi-target therapeutic strategies via network pharmacology. The integration is the unit of analysis, not any single omics modality.

## Method

This is a synthesis review, not an experimental paper. The authors organize the multi-omics analysis pipeline into three coupled stages.

Omics-layer survey. The paper catalogs each molecular layer and its tailored assays: genomics (whole-genome / whole-exome sequencing, INCO for SNV-CNV co-localization), transcriptomics (RNA-seq, microarrays), epigenomics (BS-seq, ChIP-seq, ATAC-seq, Hi-C, ChIA-PET), proteomics (mass spectrometry), and metabolomics (mass spectrometry).

ML algorithm catalog. Supervised methods are reviewed for biomarker classification and survival/regression tasks; the paper cites Reel et al.'s 1-4 attribute scoring (speed, accuracy, interpretability, computing cost, complexity, sample size) for algorithm selection. Unsupervised methods cover dimensionality reduction (PCA, blockwise sparse PCA), clustering (k-means with multi-init initialization, semi-supervised variants), and representation learning (autoencoders with adversarial training and dropout regularization). Deep models (CNN for spatial genomic patterns, RNN for time-series omics, autoencoders + network fusion for similarity-network construction) are positioned as the integration backbone for high-dimensional multi-omics.

Network pharmacology integration. Static network models (PPINs, gene regulatory, metabolic, co-expression, miRNA-gene, co-mutation, drug-gene, signaling pathway networks) integrate omics layers into testable structures via correlation, mutual information, centrality, and module detection. Dynamic network models — differential-equation-based, logic-based (CNORode), and stoichiometric (genome-scale metabolic models) — capture temporal regulation but require time-resolved data and parameter estimation. Tools surveyed include STRING, DPPN-SVM, NetworkAnalyst, mCADRE, RAVEN, WGCNA, CoExp, Pajek, and DGIdb.

## Results

The review's outputs are taxonomic and qualitative, not benchmark numbers. Three syntheses are surfaced.

ML-by-omics matching matrix. The paper tabulates which ML families have been productively applied to each omics layer: autoencoder + network fusion, MCFS, SVM, PCA-similarity for transcriptomics; PCA, k-means, SVM, RF, KNN, naive Bayes for metabolomics; RF, ANN, logistic regression, SVM, CNN, DNN for genomics; linear models, PCA, k-means for proteomics; PCA, naive Bayes, SVM, RF, RNN for epigenomics.

Network-model-by-application matrix. Each network class (PPIN, GRN, signaling pathway, metabolic, co-expression, miRNA-gene, co-mutation, drug-gene) is mapped to specific applications (functional module identification, dysregulated pathway detection, metabolic rewiring, co-expression biomarker discovery, drug response prediction).

Cross-omics integration patterns. Transcriptomics + metabolomics emerges as the most-used integrative combination; metabolomics + epigenomics is highlighted for cancer because of metabolite-driven epigenetic regulation (TCA cycle intermediates, oncometabolites such as succinate, fumarate, alpha-KG modulating chromatin-modifying enzymes); genomics + metabolomics is recommended for rare-disease causal-variant pinpointing.

## Limitations

The paper is itself a review and inherits limitations from its sources, but it also flags persistent methodological problems that no single technique solves: ML on omics data faces feature-feature dependence (violating logistic regression's independence assumption), interpretability deficits in DNNs and autoencoders (latent features represent abstract combinations of attributes), batch effects across platforms and labs, and the need for normalization (e.g., log transformation for skewed biomarkers). Per-omics-type feature selection lacks stable, validated procedures for power calculations, hindering translational use. Dynamic network models require time-resolved data and parameter estimation that are difficult to obtain reliably. K-means assumes equal cluster variance and is sensitive to initialization, both poorly aligned with multi-omics noise structure. KNN-based imputation of missing metabolite values assumes missingness at random, which metabolomics data typically violates. Static network models miss temporal dynamics; dynamic ones face parameter-uncertainty propagation. The review itself also lacks a reproducibility benchmark: it does not pit any pair of methods against each other on a shared dataset.

## Open questions

How can ML pipelines on multi-omics data be made interpretable enough for clinical adoption, given that DNNs and autoencoders produce abstract latent features?

Which integrative multi-omics combinations (transcriptomics + metabolomics? metabolomics + epigenomics? all four layers?) yield the highest incremental clinical signal, and is that ordering disease-specific?

How should batch effects and inter-laboratory heterogeneity be handled so that biomarker panels generalize across cohorts and platforms?

Can dynamic network models be reliably parameterized from currently available time-resolved omics data, or do new experimental protocols need to come first?

How do oncometabolite-driven epigenetic alterations (succinate, fumarate, alpha-KG) propagate into actionable therapeutic targets, and can multi-omics network models capture this metabolism-epigenetics cross-talk quantitatively?

## My take

The strongest contribution of the review is its insistence that the integration layer — not any single ML algorithm or omics assay — is the bottleneck. The catalog format makes it useful as a lookup table for "which ML model has prior art on which omics layer", and the network pharmacology framing connects the ML side cleanly to the multi-target therapeutics agenda. The weakest part is exactly what reviews of fast-moving fields tend to produce: breadth without comparative benchmarks. A reader cannot tell from this paper whether autoencoder + network fusion actually outperforms simpler PCA + RF on a held-out cohort, or whether the apparent dominance of any method reflects citation bias and dataset availability rather than method quality. The metabolism-epigenetics cross-talk discussion (oncometabolites driving chromatin modification) is the most concrete novel angle and is the part most worth following up. As a starting map for the multi-omics-to-targeted-therapy pipeline, this paper is useful; as a basis for choosing methods on a specific disease, it would need to be paired with empirical comparative work.

## Related

[[multi-omics-integration]]
[[multi-omics-ml-network-pharmacology-enables]]
